Home: Oncology Leader Commentary: Kathy I. Pritchard, MD

Click on the topic below for comments by Dr Kathy I. Pritchard to comment on. You will also find links to related articles and clinical trials.

First-line trials of adjuvant Arimidex
Mechanism of action of Faslodex
Faslodex intramuscular injection
Faslodex and hot flashes
Faslodex and bone metabolism
Overview data on ovarian ablation
Adjuvant Zoladex
Endocrine effects of adjuvant chemotherapy

Faslodex and bone metabolism

Interview with Neil Love, MD from Breast Cancer Update for Medical Oncologists, Program 5 2000

Play Audio Below:

There’s a little bit of data in some bone models with Faslodex that suggests its effects may be neutral or even slightly positive. That’s sort of an unexpected, to me, from what I understand about the drug. I guess again it may relate to the types of receptor and tissue specific effects with different receptor and different receptor tracks. I believe that Faslodex down regulates both alpha and beta estrogen receptor, but I think it’s now known with all of the coregulators, and so on, that there could be a number of other more complicated things going on that may be different from one tissue to another. So that it’s possible that a drug like this is not a pure antiestrogen at all, that it’s again one of these complex differential drugs that may interact differently with receptors in bone than in some other tissues. But I would think long term osteoporosis and potentially heart disease are issues that are going to have to be explored with it.

Relevant Links:

Is ICI 182,780 an antiprogestin in addition to being an antiestrogen?
Zand, R. S. R.; Grass, L.; Magklara, A.; Jenkins, D. J. A., and Diamandis, E. P. (Reprint available from: Zand RSR Mt Sinai Hosp, Dept Pathol & Lab Med 600 Univ Ave Toronto ON M5G 1X5 Canada). Breast Cancer Research & Treatment. 60(1):1-8, 2000 Mar.

Selective estrogen receptor modulators: Structure, function, and clinical use [Review].
Osborne, C. K. and Fuqua, S. A. W. Journal of Clinical Oncology. 18(17):3172-3186, 2000 Sep.

Development of a novel, "pure" antiestrogen.
Howell, A.; Osborne, C. K.; Morris, C., and Wakeling, A. E. ICI 182,780 (Faslodex (TM)) -. Cancer. 89(4):817-825, 2000 Aug 15.

Similarities and distinctions in the mode of action of different classes of antioestrogens [Review].
Wakeling, A. E. Endocrine-Related Cancer. 7(1):17-28, 2000 Mar. No abstract

Approaches targeted to estrogen receptors for treatment of tamoxifen-resistant breast cancer: A brief overview.
Terakawa, N. (Reprint available from: Terakawa N Tottori Univ, Sch Med, Dept Obstet & Gynecol Yonago Tottori 683 Japan).. Oncology. 59(Suppl 1):3-4, 2000. No abstract

Treatment with the pure antiestrogen faslodex (ICI 182780) induces tumor necrosis factor receptor 1 (TNFR1) expression in MCF-7 breast cancer cells.
Smolnikar, K.; Loffek, S.; Schulz, T.; Michna, H., and Diel, P. (Reprint available from: Smolnikar K DSHS Cologne, Inst Morphol & Tumor Res Carl Diem Weg 6 D-50927 Cologne Germany). Breast Cancer Research & Treatment. 63(3):249-259, 2000 Oct. In process

Symposium overview: Estrogens and antiestrogens in managing the patient with breast cancer.
Newman, L. A.; Wood, W. C.; Sellin, R. V.; Morrow, M.; Vogel, C., and Singletary, S. E (Reprint available from: Singletary SE Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol 1515 Holcombe Blvd,Box 106 Houston, TX 77030 USA).. Annals of Surgical Oncology. 7(8):568-574, 2000 Sep. In process

Top of Page